T1	Participants 0 61	Comparison of inhaled albuterol powder and aerosol in asthma.
T2	Participants 71 205	multicenter, randomized, double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation
T3	Participants 207 232	231 patients with chronic
T4	Participants 530 549	period of 12 weeks.
T5	Participants 610 759	the powder and aerosol formulations with respect to pulmonary function, length of time mean FEV1 remained greater than or equal to 15% above baseline
T6	Participants 873 988	no significant differences between treatment groups in cardiovascular effects, laboratory values, or adverse events
T7	Participants 1109 1236	this study demonstrate that 200 micrograms of albuterol powder is as safe and effective as 180 micrograms of albuterol aerosol.
T8	Participants 1065 1096	half preferred using the powder
